Opendata, web and dolomites

IL7RsignaTHER SIGNED

Antibody-based IL-7R targeted therapies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 IL7RsignaTHER project word cloud

Explore the words cloud of the IL7RsignaTHER project. It provides you a very rough idea of what is the project "IL7RsignaTHER" about.

signaling    treatment    pediatric    scenario    antibody    leukemic    plays    therapeutic    cell    40    chronic    innovative    childhood    preliminary    cog    inflammatory    children    648455    expression    risk    cancer    autoimmune    peripheral    detrimental    aggressive    worse    dismal    market    diseases    remarkable    acute    malignancy    cells    disease    strategies    lymphoid    7r    complications    erc    frequent    lung    remission    minimize    pathological    monoclonal    indications    led    adults    rheumatoid    cancers    broad    multiple    il7signeture    generate    relapses    conventional    breast    biopharmaceuticals    colorectal    dependence    commercialize    malignancies    melanoma    consolidator    free    surface    extends    efficient    leukemia    outcome    grant    glioblastoma    80    hematological    data    obvious    considerably    severe    lymphocytic    lymphoblastic    adjusted    agent    ectopic    improvement    sclerosis    diabetes    prognosis    alive    lymphoma    bladder    unmet    regimens    solid    bowel    axis    il    intensive    arthritis    mediated    chemotherapy    hodgkin    explore    therapies   

Project "IL7RsignaTHER" data sheet

The following table provides information about the project.

Coordinator
INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES 

Organization address
address: AVENIDA PROF EGAS MONIZ
city: LISBOA
postcode: 1649 028
website: www.imm.ul.pt

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES PT (LISBOA) coordinator 150˙000.00

Map

 Project objective

Acute lymphoblastic leukemia (ALL), a highly aggressive hematological cancer, is the most frequent childhood malignancy and the second most common acute leukemia in adults. The use of risk-adjusted multi-agent intensive chemotherapy has led to a remarkable improvement in treatment outcome of pediatric cases, with more than 80% of children with ALL being alive and disease-free at 5 years. However, a significant number of relapses still occur, whose prognosis is dismal, and the intensive regimens used are often associated with long-term, severe complications. In adults, the scenario is considerably worse: only 30–40% of the cases achieve long-term remission. Therefore, there is an obvious unmet need, and a major challenge, to develop novel, more efficient therapeutic strategies that specifically target the leukemic cells, minimize the detrimental side effects associated with conventional therapies and improve overall treatment outcome. Based on exciting and robust preliminary data from our ERC Consolidator Grant IL7sigNETure (CoG-648455), we now propose to explore the dependence of ALL cells on IL-7/IL-7R-mediated signaling and the broad expression of IL-7R on the surface of ALL cells to develop and commercialize novel monoclonal antibody-based biopharmaceuticals that we will generate targeting the IL-7/IL-7R axis for treatment of this malignancy. Our innovative therapeutic strategies have significant market potential that extends beyond ALL. Other possible indications include other lymphoid malignancies (Hodgkin's lymphoma, peripheral T-cell lymphoma, chronic lymphocytic leukemia), solid cancers with ectopic expression of IL-7R (including melanoma, breast, lung, bladder and colorectal cancer, or glioblastoma), and autoimmune and chronic inflammatory diseases (diabetes, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease) in which the IL-7/IL-7R axis plays a pathological role.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IL7RSIGNATHER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IL7RSIGNATHER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

DISINTEGRATION (2019)

The Mass Politics of Disintegration

Read More  

SUExp (2018)

Strategic Uncertainty: An Experimental Investigation

Read More